Iteria Biopharma

iteriabiopharma.com ↗ ·A Coruña ·Seed

Spanish biopharmaceutical company founded in 2024 (spun out of GalChimia) that discovers and develops first-in-class precision drugs for hard-to-treat, treatment-resistant cancers, with a lead program (ITR-251) targeting metastatic castration-resistant prostate cancer plus programs in pancreatic, colorectal and lung cancer. Closed a €5M Series Seed round in April 2026 led by Inveready with Xesgalicia and the founding partners.

Founded

2024

Founders

Total funds raised

€5M

SectorsOncology, Biopharmaceuticals, Drug Discovery Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Carme Pampín

Co-Founder (also CEO of GalChimia)

Julio Castro

Co-Founder (also CEO of Palobiofarma)

Also at Palobiofarma

Ramon Bosser

CEO & Co-Founder

Global models 5

Treeline Biosciences

United States · www.treeline.bio ↗

Privately held, VC-backed biotech that discovers and develops its own first-in-class precision small-molecule drugs for hard-to-treat cancers.

~$1.1BComparable

Relay Therapeutics

United States · relaytx.com ↗

Raised venture money before its IPO to discover precision small molecules against oncogenic targets in treatment-resistant tumours, and runs its own pipeline.

~$520MComparable

Scorpion Therapeutics

United States · scorpiontx.com ↗

VC-funded discovery company that built its own pipeline of precision oncology drugs aimed at resistant cancers, then monetised it through a pharma exit (Eli Lilly).

~$270MComparable

Boundless Bio

United States · boundlessbio.com ↗

Raised venture money before its IPO to develop first-in-class precision medicines for oncogene-amplified cancers with no approved treatments.

~$250MComparable

Revolution Medicines

United States · www.revmed.com ↗

Raised venture money before its IPO to discover first-in-class targeted drugs for RAS-driven pancreatic, colorectal and lung cancers, which are also Iteria's indications.

~$200MComparable